25,603 Shares in Abbott Laboratories (NYSE:ABT) Purchased by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. acquired a new position in shares of Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 25,603 shares of the healthcare product maker’s stock, valued at approximately $2,896,000.

Other institutional investors have also modified their holdings of the company. Nia Impact Advisors LLC increased its position in Abbott Laboratories by 2.8% during the fourth quarter. Nia Impact Advisors LLC now owns 3,812 shares of the healthcare product maker’s stock valued at $431,000 after acquiring an additional 105 shares during the last quarter. NorthRock Partners LLC boosted its stake in shares of Abbott Laboratories by 166.4% during the 4th quarter. NorthRock Partners LLC now owns 46,041 shares of the healthcare product maker’s stock worth $5,208,000 after purchasing an additional 28,757 shares during the period. Northwest Quadrant Wealth Management LLC grew its holdings in Abbott Laboratories by 8.9% during the 4th quarter. Northwest Quadrant Wealth Management LLC now owns 2,422 shares of the healthcare product maker’s stock valued at $274,000 after purchasing an additional 198 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new stake in Abbott Laboratories in the 4th quarter worth about $457,000. Finally, OMERS ADMINISTRATION Corp boosted its position in shares of Abbott Laboratories by 0.6% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 1,015,378 shares of the healthcare product maker’s stock valued at $114,849,000 after buying an additional 6,264 shares during the period. 75.18% of the stock is owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the firm’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director now owns 34,058 shares of the company’s stock, valued at approximately $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Lisa D. Earnhardt sold 91,167 shares of Abbott Laboratories stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares of the company’s stock, valued at $9,625,404.96. The trade was a 55.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 95,278 shares of company stock valued at $12,745,859 in the last quarter. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 2.3%

Shares of NYSE ABT opened at $129.02 on Wednesday. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The business has a fifty day moving average price of $129.57 and a 200 day moving average price of $123.72. The stock has a market capitalization of $224.47 billion, a P/E ratio of 16.87, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.83%. Abbott Laboratories’s dividend payout ratio is presently 30.61%.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent analyst reports. The Goldman Sachs Group increased their price target on Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. UBS Group increased their target price on Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Argus raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Tuesday, January 28th. Barclays upped their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a report on Thursday, April 17th. Finally, Bank of America lifted their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 10th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $142.59.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.